Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV001839258 | SCV002099230 | pathogenic | Kleefstra syndrome 2 | 2021-04-13 | criteria provided, single submitter | clinical testing | The de novo ~243kb deletion deletes the last 53 exons (exon 7-59) of the KMT2C gene. The majority of pathogenic variants in KMT2C are nonsense or frameshift [PMID: 29069077; PMID: 32366967], suggesting loss-of-function is the likely mechanism of the disease. ClinGen Dosage Sensitivity curation [https://search.clinicalgenome.org/kb/gene-dosage/HGNC:13726] indicates that the KMT2C gene has a haploinsufficiency score of 3 (i.e.,sufficient evidence for haploinsufficiency). Based on the available evidence, this de novo ~243kb deletion is classified as pathogenic. |